Jazz Pharmaceuticals plc logo
Jazz Pharmaceuticals plc JAZZ
$ 187.2 -1.48%

Annual report 2025
added 02-24-2026

report update icon

Jazz Pharmaceuticals plc Financial Ratios 2011-2026 | JAZZ

Annual Financial Ratios Jazz Pharmaceuticals plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-29.6 15.9 19.8 -39.2 -24.9 39.2 16.0 17.2 18.8 18.6 24.6 181.6 44.6 11.9 17.5

P/S

2.5 2.2 2.1 2.4 2.7 4.0 3.9 4.1 5.7 5.0 6.1 9.0 11.1 5.9 8.0

EPS

-5.8 9.1 6.5 -3.6 -5.5 4.3 9.2 7.5 8.1 6.6 5.4 1.0 3.7 5.1 3.0

EV (Enterprise Value)

9.15 B 6.48 B 6.71 B 7.91 B 7.61 B 8.3 B 10.2 B 9.82 B 11.2 B 9.94 B 8.86 B 11.9 B 9.95 B 3.89 B 2.17 B

EBITDA per Share

-6.37 12.1 9.62 -0.56 3.3 7.12 15.7 13.6 11.3 11.4 9.51 5.26 6.8 4.52 2.87

EV/EBITDA

38.5 9.5 10.7 10.9 15.0 12.8 13.9 34.2 22.8 12.9 15.7

PEG

0.07 -0.04 -0.05 1.03 1.69 47423.47 0.65 -2.09 0.78 0.82 0.05 -2.47 -1.67 0.15 0.08

P/B

0.9 0.7 0.7 0.8 0.7 1.4 2.7 2.8 3.4 3.9 5.1 7.7 7.4 3.1 11.4

P/CF

7.8 6.4 7.5 6.9 10.5 10.4 14.1 11.5 15.9 18.1 16.4 62.9 35.4 15.1 15.0

ROE %

-8.25 13.68 11.10 -7.26 -8.31 6.52 16.82 16.21 17.98 21.14 20.61 4.26 16.70 25.74 64.84

ROA %

-3.05 4.66 3.64 -2.07 -2.68 3.65 9.45 8.59 9.52 8.27 9.89 1.75 9.66 14.68 49.29

ROCE %

-9.96 17.51 15.48 -2.12 4.29 10.33 10.29 12.63 10.95 13.01 15.82 6.26 16.55 11.14 63.08

Current Ratio

- - - - - - 4.5 3.6 3.3 2.9 5.6 4.7 4.2 2.9 3.8

DSO

66.2 63.8 64.6 60.6 56.6 58.1 60.1 50.9 50.5 57.4 57.8 58.0 52.2 47.0 46.1

DIO

- - - - - - 224.3 159.0 143.1 118.1 69.4 93.3 102.6 123.4 102.4

DPO

- - - - - - 135.7 121.9 80.8 77.6 77.6 78.0 75.1 74.0 133.9

Operating Cycle

66.2 63.8 64.6 60.6 56.6 58.1 284.4 210.0 193.6 175.6 127.2 151.3 154.8 170.4 148.5

Cash Conversion Cycle

66.2 63.8 64.6 60.6 56.6 58.1 148.7 88.0 112.8 98.0 49.6 73.2 79.7 96.4 14.6

All numbers in USD currency

Quarterly Financial Ratios Jazz Pharmaceuticals plc

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

4.14 -11.74 -1.52 3.5 2.68 -0.23 2.33 1.63 1.09 - -0.31 0.56 0.03 - -0.86 -6.11 2.16 2.39 2.67 2.07 -2.82 1.31 1.8 4.62 1.49 2.69 2.47 1.53 0.77 3.87 1.06 1.76 1.44 1.95 1.49 1.89 1.24 1.35 1.43 1.44 1.16 1.35 0.43 0.73 -1.58 0.96 1.3 0.72 0.74 3.46 0.58 0.48 0.51 0.88 0.77 0.81 0.54

EBITDA per Share

3.72 -8.57 -0.75 6.8 5.64 1.18 5.19 4.84 2.1 - 2.64 3.75 1.54 - 0.78 1.19 2.96 - 3.79 3.74 -3.31 - 2.54 3.72 2.4 - 3.31 2.67 1.53 - 1.59 2.85 2.33 - 2.39 2.87 2.02 - 2.26 2.58 1.96 - 1.05 1.3 -1.12 - 1.76 1.33 1.18 - 0.97 0.7 0.67 - 0.81 0.83 0.56

ROE %

-10.10 -11.97 7.02 13.45 11.25 8.86 8.54 3.61 1.73 0.41 -0.93 -1.55 -11.43 -6.93 -3.28 2.11 14.04 6.52 5.25 4.49 9.77 16.82 20.23 22.36 17.29 16.21 18.99 15.92 16.46 17.98 15.64 18.08 20.29 21.14 19.77 20.61 20.60 21.98 23.08 19.34 16.43 4.26 2.57 6.52 6.59 16.70 30.31 27.46 26.62 25.74 27.29 41.18 55.98 64.83 16.85 17.22 11.32

ROA %

-3.40 -4.13 2.31 4.42 3.59 2.74 2.68 1.18 0.26 -0.16 -0.58 -0.83 -3.58 -1.37 0.67 3.36 7.87 3.65 2.95 2.52 5.50 9.45 11.18 12.20 9.25 8.59 10.06 8.43 8.72 9.52 7.42 8.05 8.38 8.27 8.32 9.08 9.33 9.86 9.82 7.97 6.64 1.75 1.77 4.37 4.95 9.66 17.39 15.71 15.21 14.68 19.25 30.38 42.09 49.29 12.81 13.09 8.61

ROCE %

-12.17 -8.32 11.99 18.27 16.50 14.98 14.09 10.05 8.26 6.00 6.72 6.54 2.18 3.30 8.67 13.31 20.40 5.59 9.87 8.79 9.94 15.14 21.99 24.56 23.55 15.59 18.77 15.11 15.64 14.29 21.55 25.62 28.52 22.70 31.11 32.27 33.88 27.95 32.19 28.01 22.83 4.79 12.55 16.08 16.61 18.97 23.91 21.08 18.64 11.64 29.12 41.67 55.71 46.77 17.48 17.56 11.72

DSO

59.9 59.6 70.0 61.5 62.6 67.5 58.1 58.8 65.2 - 29.2 28.0 63.7 - 54.8 55.9 60.9 54.4 60.2 64.3 64.2 55.8 60.4 60.8 55.6 50.5 51.3 48.1 50.1 46.9 49.7 51.9 55.6 53.9 57.1 56.1 60.3 56.1 56.1 57.3 58.4 51.8 55.5 58.4 57.5 48.3 49.0 54.7 46.6 37.5 39.2 55.4 48.9 37.5 42.8 48.6 -

Operating Cycle

59.9 59.6 70.0 61.5 62.6 67.5 58.1 58.8 65.2 - 29.2 28.0 63.7 - 54.8 55.9 60.9 54.4 60.2 64.3 64.2 55.8 60.4 60.8 55.6 50.5 51.3 48.1 50.1 46.9 49.7 51.9 55.6 53.9 57.1 56.1 60.3 56.1 56.1 57.3 58.4 51.8 55.5 58.4 57.5 48.3 49.0 54.7 46.6 37.5 39.2 55.4 48.9 37.5 42.8 48.6 -

Cash Conversion Cycle

59.9 59.6 70.0 61.5 62.6 67.5 58.1 58.8 65.2 - 29.2 28.0 63.7 - 54.8 55.9 60.9 54.4 60.2 64.3 64.2 55.8 60.4 60.8 55.6 50.5 51.3 48.1 50.1 46.9 49.7 51.9 55.6 53.9 57.1 56.1 60.3 56.1 56.1 57.3 58.4 51.8 55.5 58.4 57.5 48.3 49.0 54.7 46.6 37.5 39.2 55.4 48.9 37.5 42.8 48.6 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Jazz Pharmaceuticals plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Agenus Agenus
AGEN
$ 3.27 -1.8 % $ 1.17 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.33 -2.98 % $ 1.7 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.26 -3.44 % $ 324 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 0.24 1.1 % $ 5.73 B britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 5.49 0.52 % $ 330 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alector Alector
ALEC
$ 2.26 -7.2 % $ 233 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 7.02 -0.21 % $ 451 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 29.32 -2.61 % $ 4.83 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 2.57 -7.73 % $ 403 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.95 -0.59 % $ 43.4 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Altimmune Altimmune
ALT
$ 4.2 -2.55 % $ 298 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 2.11 0.09 % $ 110 M usaUSA
Amgen Amgen
AMGN
$ 387.85 0.03 % $ 209 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.22 -0.05 % $ 945 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.62 -1.3 % $ 5.55 B irlandaIrlanda
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.92 5.25 % $ 44.2 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 54.61 -0.8 % $ 1.55 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.44 0.53 % $ 212 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 75.31 1.91 % $ 1.45 B usaUSA
Annexon Annexon
ANNX
$ 5.38 -3.93 % $ 739 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 2.6 -2.99 % $ 23.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.53 -2.05 % $ 2.59 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.78 -0.67 % $ 4.25 M chinaChina
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.88 -3.71 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 7.28 -0.55 % $ 2.01 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 3.99 -0.15 % $ 346 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.11 -1.44 % $ 219 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.32 -3.54 % $ 1.52 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
argenx SE argenx SE
ARGX
$ 762.51 -0.58 % $ 25 B niderlandNiderland